Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Myocardial fibrosis is a key process in diabetic cardiomyopathy. However, their underlying mechanisms have not been elucidated, leading to a lack of therapy. The glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, reduces hyperglycemia but may also trigger direct effects on the heart. METHODS: Goto-Kakizaki (GK) rats developed type-II diabetes and received sitagliptin, an anti-hyperglycemic drug (metformin) or vehicle (n=10, each). After cardiac structure and function assessment, plasma and left ventricles were isolated for biochemical studies. Cultured cardiomyocytes and fibroblasts were used for in vitro assays. RESULTS: Untreated GK rats exhibited hyperglycemia, hyperlipidemia, plasma GLP-1 decrease, and cardiac cell-death, hypertrophy, fibrosis and prolonged deceleration time. Moreover, cardiac pro-apoptotic/necrotic, hypertrophic and fibrotic factors were up-regulated. Importantly, both sitagliptin and metformin lessened all these parameters. In cultured cardiomyocytes and cardiac fibroblasts, high-concentration of palmitate or glucose induced cell-death, hypertrophy and fibrosis. Interestingly, GLP-1 and its insulinotropic-inactive metabolite, GLP-1(9-36), alleviated these responses. In addition, despite a specific GLP-1 receptor was only detected in cardiomyocytes, GLP-1 isoforms attenuated the pro-fibrotic expression in cardiomyocytes and fibroblasts. In addition, GLP-1 receptor signalling may be linked to PPARδ activation, and metformin may also exhibit anti-apoptotic/necrotic and anti-fibrotic direct effects in cardiac cells. CONCLUSIONS: Sitagliptin, via GLP-1 stabilization, promoted cardioprotection in type-II diabetic hearts primarily by limiting hyperglycemia e hyperlipidemia. However, GLP-1 and GLP-1(9-36) promoted survival and anti-hypertrophic/fibrotic effects on cultured cardiac cells, suggesting cell-autonomous cardioprotective actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Claycomb, W. C., Lanson, N. A., Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A., & Izzo, N. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2979 · Cited by 1,546 · cited 1×
“Zalba, Pamplona, Spain) [18] retain differentiated cardiac morphological, biochemical, and electrophysiological properties, and exhibit a pattern of gene expression similar to that of adult myocytes [19].”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 3×
“Thus, besides its insulin-dependent glycemic and lipidemic control, sitagliptin might play salutary roles by direct actions of GLP-1 on cardiac cells [6].”
BackgroundMojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“peroxisome proliferator activating receptor-δ (PPARδ) [28, 29].”
Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options
Aneja, A., Tang, W. H. W., Bansilal, S., Garcia, M. J., & Farkouh, M. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.046 · Cited by 482 · cited 8×
“(ECM) deposition from fibroblasts and myocytes [2,3].”
InfluentialYan, W., Zhang, H., Liu, P., Wang, H., Liu, J., Gao, C., Liu, Y., Lian, K., Yang, L., Sun, L., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0329-1 · Cited by 169
Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130 · cited 1×
“decreased under hyperglycemia [55].”
Research works printed but not linked: 44
- S Chen, 2000, Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors, J Mol Cell Cardiol, 32, 1621, 10.1006/jmcc.2000.1197 · DOI
- K Mizushige, 2000, Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model, Circulation, 101, 899, 10.1161/01.CIR.101.8.899 · DOI · Paper page
- DJ Drucker, 2007, Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action, Diabetes Care, 30, 1335, 10.2337/dc07-0228 · DOI · Paper page
- S Mudaliar, 2012, The incretin hormones: from scientific discovery to practical therapeutics, Diabetologia, 55, 1865, 10.1007/s00125-012-2561-x · DOI
- H Hui, 2010, Glucagon like peptide-1-directed human embryonic stem cells differentiation into insulin-producing cells via hedgehog, cAMP, and PI3K pathways, Pancreas, 39, 315, 10.1097/MPA.0b013e3181bc30dd · DOI
- DA Glauser, 2007, Transcriptional response of pancreatic beta cells to metabolic stimulation: large scale identification of immediate-early and secondary response genes, BMC Mol Biol, 8, 54, 10.1186/1471-2199-8-54 · DOI
- K-D Wagner, 2010, Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions, Pharmacol Ther, 125, 423, 10.1016/j.pharmthera.2009.12.001 · DOI · Paper page
- H Zhang, 2007, PPARbeta/delta activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts, Arch Biochem Biophys, 460, 25, 10.1016/j.abb.2007.01.028 · DOI
- C-G Ostenson, 2007, Islet gene expression and function in type 2 diabetes; studies in the Goto-Kakizaki rat and humans, Diabetes Obes Metab, 9, 180, 10.1111/j.1463-1326.2007.00787.x · DOI
- A Tahara, 2009, Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors, Pharmacol Rep, 61, 899, 10.1016/S1734-1140(09)70147-1 · DOI
- C Orskov, 1987, Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), Scand J Clin Lab Invest, 47, 165, 10.3109/00365518709168885 · DOI
- EM Escudero, 2004, Echocardiographic assessment of left ventricular midwall mechanics in spontaneously hypertensive rats, Eur J Echocardiogr, 5, 169, 10.1016/j.euje.2003.11.004 · DOI
- S Ravassa, 2011, Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes, Am J Physiol Heart Circ Physiol, 300, H1361, 10.1152/ajpheart.00885.2010 · DOI · Paper page
- R Martín, 2012, DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy, PLOS ONE, 7, e41545, 10.1371/journal.pone.0041545 · DOI
- F Strutz, 1995, Identification and characterization of a fibroblast marker: FSP1, J Cell Biol, 130, 393, 10.1083/jcb.130.2.393 · DOI · Paper page
- DLM Hickson-Bick, 2002, Palmitate-induced apoptosis in neonatal cardiomyocytes is not dependent on the generation of ROS, Am J Physiol Heart Circ Physiol, 282, H656, 10.1152/ajpheart.00726.2001 · DOI · Paper page
- Y Ishibashi, 2011, Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells, Horm Metab Res, 43, 731, 10.1055/s-0031-1284383 · DOI
- S Ares-Carrasco, 2012, Proteome changes in the myocardium of experimental chronic diabetes and hypertension: Role of PPARα in the associated hypertrophy, J Proteomics, 75, 1816, 10.1016/j.jprot.2011.12.023 · DOI
- S Dhillon, 2010, Sitagliptin: a review of its use in the management of type 2 diabetes mellitus, Drugs, 70, 489, 10.2165/11203790-000000000-00000 · DOI
- Y Ye, 2010, The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA, Am J Physiol Heart Circ Physiol, 298, H1454, 10.1152/ajpheart.00867.2009 · DOI · Paper page
- P Anagnostis, 2011, Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control, Diabetes Obes Metab, 13, 302, 10.1111/j.1463-1326.2010.01345.x · DOI · Paper page
- M Rajesh, 2010, Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy, J Am Coll Cardiol, 56, 2115, 10.1016/j.jacc.2010.07.033 · DOI · Paper page
- S Ares-Carrasco, 2009, Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes, Am J Physiol Heart Circ Physiol, 297, H2109, 10.1152/ajpheart.00157.2009 · DOI
- A D’Souza, 2011, Left Ventricle Structural Remodelling in the Prediabetic Goto-Kakizaki Rat, Exp Physiol, 96, 875, 10.1113/expphysiol.2011.058271 · DOI
- BH Lorell, 2000, Left ventricular hypertrophy: pathogenesis, detection, and prognosis, Circulation, 102, 470, 10.1161/01.CIR.102.4.470 · DOI · Paper page
- TJ Regan, 1983, Congestive heart failure in the diabetic, Annu Rev Med, 34, 161, 10.1146/annurev.me.34.020183.001113 · DOI · Paper page
- M Lenski, 2011, Effects of DPP-4 inhibition on cardiac metabolism and function in mice, J Mol Cell Cardiol, 51, 906, 10.1016/j.yjmcc.2011.08.001 · DOI
- M Rendell, 2012, Alogliptin benzoate for the treatment of type 2 diabetes, Expert Opin Pharmacother, 13, 553, 10.1517/14656566.2012.656088 · DOI
- J Rosenstock, 2008, Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes, Diabetes Obes Metab, 10, 376, 10.1111/j.1463-1326.2008.00876.x · DOI · Paper page
- G Mellitzer, 2011, Enteroendocrine cells and lipid absorption, Curr Opin Lipidol, 22, 171, 10.1097/MOL.0b013e32834622a2 · DOI
- M Cobble, 2012, Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus, 10.1186/1758-5996-4-8 · DOI
- M Sauvé, 2010, Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice, Diabetes, 59, 1063, 10.2337/db09-0955 · DOI · Paper page
- Y Ishibashi, 2012, Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A, Microvasc Res, 84, 395, 10.1016/j.mvr.2012.06.008 · DOI
- A Mima, 2012, Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes, Diabetes, 61, 2967, 10.2337/db11-1824 · DOI · Paper page
- PA Read, 2010, DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease, Circ Cardiovasc Imaging, 3, 195, 10.1161/CIRCIMAGING.109.899377 · DOI · Paper page
- R Gros, 2003, Cardiac function in mice lacking the glucagon-like peptide-1 receptor, Endocrinology, 144, 2242, 10.1210/en.2003-0007 · DOI · Paper page
- E Tomas, 2010, Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis, Trends Endocrinol Metab, 21, 59, 10.1016/j.tem.2009.11.007 · DOI · Paper page
- X-F Wang, 2011, Beneficial effects of metformin on primary cardiomyocytes via activation of adenosine monophosphate-activated protein kinase, Chin Med J (Engl), 124, 1876
- H Xiao, 2010, Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway, Cardiovasc Res, 87, 504, 10.1093/cvr/cvq066 · DOI · Paper page
- H Oeseburg, 2010, Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A, Arterioscler Thromb Vasc Biol, 30, 1407, 10.1161/ATVBAHA.110.206425 · DOI · Paper page
- KA Burns, 2007, Modulation of PPAR activity via phosphorylation, Biochim Biophys Acta, 1771, 952, 10.1016/j.bbalip.2007.04.018 · DOI · Paper page
- N Wagner, 2009, Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin, Cardiovasc Res, 83, 61, 10.1093/cvr/cvp106 · DOI
- SC Fan, 2010, The decreased expression of peroxisome proliferator-activated receptors delta (PPARdelta) is reversed by digoxin in the heart of diabetic rats, Horm Metab Res, 42, 637, 10.1055/s-0030-1253373 · doi:10.1055/s-0030-1253373
- HJ Kim, 2009, Peroxisome proliferator-activated receptor {delta} regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/Smad3, Circ Res, 105, 16, 10.1161/CIRCRESAHA.108.189159 · DOI
Cited by
Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential
Faria, A., & Persaud, S. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.013 · Cited by 295
Varga, Z. V., Giricz, Z., Liaudet, L., Haskó, G., Ferdinandy, P., & Pacher, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.030 · Cited by 286
Experimental animal models for diabetes and its related complications—a review
Kottaisamy, C. P. D., Raj, D. S., Prasanth Kumar, V., & Sankaran, U. (2021) · Laboratory Animal Research · doi:10.1186/s42826-021-00101-4 · Cited by 263
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Marques, C., Mega, C., Gonçalves, A., Rodrigues-Santos, P., Teixeira-Lemos, E., Teixeira, F., Fontes-Ribeiro, C., Reis, F., & Fernandes, R. (2014) · Mediators of Inflammation · doi:10.1155/2014/538737 · Cited by 126
“It was recently suggested that sitagliptin, via GLP1 stabilization, is able to promote cardioprotection in a model of type 2 diabetic by reducing and limiting hyperglycemia and hyperlipidemia, as well as by promotion of survival and antihypertrophic/fibrotic effects on cultured cardiac cells, via GLP-1 and GLP-1(9-36)…”
BackgroundTang, S.-T., Zhang, Q., Tang, H.-Q., Wang, C.-J., Su, H., Zhou, Q., Wei, W., Zhu, H.-Q., & Wang, Y. (2016) · Endocrine · doi:10.1007/s12020-015-0852-y · Cited by 46
Metadata
- Authors
- Picatoste, B., Ramírez, E., Caro-Vadillo, A., Iborra, C., Egido, J., Tuñón, J., & Lorenzo, Ó.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-21
- Volume
- 8
- Issue
- 10
- Pages
- e78330
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2001535323
- Cited by
- 101
- References
- 10
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-02-28)
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms. https://app.cochat.ai/papers/10.1371/journal.pone.0078330
- The paper
- Picatoste, B., Ramírez, E., Caro-Vadillo, A., Iborra, C., Egido, J., Tuñón, J., & Lorenzo, Ó. (2013). Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms. PLoS ONE. https://doi.org/10.1371/journal.pone.0078330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.